Correction: Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders

Correction to: Genetics in Medicine21:2019; https://doi.org/10.1038/s41436-019-0554-6, published online 11 June 2019 In our meta-analysis, we utilized incorrect numbers of individuals for one publication (Retterer et al. 2016) due to the fact the numbers for ASD and ID groups were not independent representations. We have updated our analysis using corrected numbers based on correspondence with the first author of this paper (diagnostic yield for NDD=543/1736 as opposed to 570/2063). The updated analysis leads to the same (rounded) weighted diagnostic yield and confidence intervals (CI) as the initial publication (36% [30–43%]). The updated analysis results in the following updated values in Fig. 2: Retterer study values: N positive=543, N total=1736, study weight=5.3% and meta-analysis statistics: I2=80%, τ2 = 0.2835, p<0.01. The study is also included in two subanalyses reported in the Results. The isolated NDD subcategory (n=21 articles), updated analysis leads to same (rounded) weighted diagnostic yield and confidence intervals as published (31% [25–38%]). For the subanalysis of mix of ID and/or ASD, the initial yield was 37% (CI: 29–46%). Following updated analysis, the yield of this subset is 39% (CI: 29–50%). The PDF and HTML versions of the Article have been modified accordingly. These authors contributed equally: Siddharth Srivastava, Jamie A. Love-Nichols. The original article can be found online at https://doi.org/10.1038/s41436-019-0554-6. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersGenetics in MedicineVol. 21Issue 11PreviewFor neurodevelopmental disorders (NDDs), etiological evaluation can be a diagnostic odyssey involving numerous genetic tests, underscoring the need to develop a streamlined algorithm maximizing molecular diagnostic yield for this clinical indication. Our objective was to compare the yield of exome sequencing (ES) with that of chromosomal microarray (CMA), the current first-tier test for NDDs. Full-Text PDF Open Access